Endovascular versus medical therapy for atherosclerotic renovascular disease - Wikidata - wikimedia - TriplyDB

Endovascular versus medical therapy for atherosclerotic renovascular disease

Endovascular versus medical therapy for atherosclerotic renovascular disease

http://www.wikidata.org/entity/Q36760787

about

Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.The efficacy of renal artery stent combined with optimal medical therapy in patients with severe atherosclerotic renal artery stenosis.

P2860

Q49609545-F08559B2-5AD9-40BC-8078-EB745583A071 Q51124591-A5F4DE59-413B-4190-AF3E-72C3B4F94912

P2860

Endovascular versus medical therapy for atherosclerotic renovascular disease

http://www.wikidata.org/entity/Q36760787

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Endovascular versus medical therapy for atherosclerotic renovascular disease

@ast

Endovascular versus medical therapy for atherosclerotic renovascular disease

@en

type

label

Endovascular versus medical therapy for atherosclerotic renovascular disease

@ast

Endovascular versus medical therapy for atherosclerotic renovascular disease

@en

prefLabel

Endovascular versus medical therapy for atherosclerotic renovascular disease

@ast

Endovascular versus medical therapy for atherosclerotic renovascular disease

@en

P1433

Q36760787-EBF906E6-B27E-4306-B9AD-02B0F8C29EE4

P1476

Q36760787-08D70275-3273-41D8-AC32-A27F54420F13

P2093

Q36760787-2DEB0A87-F4A9-423B-AF73-23FD317FD1F1

Q36760787-471D80F3-5BB6-41A5-88DA-3DB1D2A2AAFD

Q36760787-5077A63B-38CE-4463-B868-25C176E40329

Q36760787-7036ED51-F5AB-42C3-B5E4-389358CA5E34

Q36760787-AA9E6318-A364-46F2-9C90-9D2ACCD6916B

Q36760787-C5DFBBEF-FD2D-4721-984B-C22CFB59D329

Q36760787-CD5ABC5A-B161-4C5B-9014-3A87F8256E94

P2860

Q36760787-02F9798A-BED1-4E00-A7C2-C7641DE1DFA8

Q36760787-09EE99AB-E801-4855-B1F6-93098766628F

Q36760787-0D4CC181-CC4E-4C74-AC5D-1522098B40D1

Q36760787-1066FF19-08B9-41B4-9350-8476EAB7E946

Q36760787-10A50D36-7885-4C14-B5F5-09C2479B3C60

Q36760787-14849149-3BDC-480E-B556-7DA0F725CC9C

Q36760787-1AD4C1F5-9F09-4857-98DA-4B238EEEDDA9

Q36760787-1E378A87-B7D9-4ECC-AA15-83482B4BAFA7

Q36760787-21067B97-6F03-409A-BEB8-F212A3F55965

Q36760787-24723CC5-E0B9-4672-A1E8-9B36927EA3BC

P2888

Q36760787-8C499685-2112-4C8E-89C4-E4D4DF859941

P304

Q36760787-C06C2FF2-C016-4565-9670-FD9DB126B68C

P31

Q36760787-852F4A1D-56A3-4460-9655-BC648CC231F8

P356

Q36760787-14C556A9-AF3C-48B9-B711-AB26F6CCEE4D

P433

Q36760787-26176089-4DFB-4AFB-A797-42A10D16F90B

P478

Q36760787-0B8E2C14-929A-451D-98B2-E4D7E2ECBBAE

P50

Q36760787-888AD43C-4D48-4475-920A-7F3C8E780FD3

P577

Q36760787-956FC3D6-71DF-4814-81D2-27D2680056F7

P5875

Q36760787-AA6C2764-9027-4A7B-887C-F768DCA54BA6

P698

Q36760787-D0C58AAF-7A40-4EE8-A89A-D91FC1BDA2E8

P921

Q36760787-E5FB8093-5E30-4508-BFC7-649505C59371

P932

Q36760787-4B2A126C-B8A8-43FE-AF85-BB475F80F118

P356

S11883-014-0459-4

P1433

Current Atherosclerosis Reports

P1476

Endovascular versus medical therapy for atherosclerotic renovascular disease

@en

P2093

Christopher J Cooper

http://www.w3.org/2001/XMLSchema#string

David A Folt

http://www.w3.org/2001/XMLSchema#string

Emily L Cooper

http://www.w3.org/2001/XMLSchema#string

Kaleigh L Evans

http://www.w3.org/2001/XMLSchema#string

Mark Shipeng Yu

http://www.w3.org/2001/XMLSchema#string

Pamela Brewster

http://www.w3.org/2001/XMLSchema#string

Steven T Haller

http://www.w3.org/2001/XMLSchema#string

P2860

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Renal artery stenosis-when to screen, what to stent?

Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Glucose control and vascular complications in veterans with type 2 diabetes

P2888

s11883-014-0459-4

P304

459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11883-014-0459-4

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Christopher A Drummond

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266747058

http://www.w3.org/2001/XMLSchema#string

P698

25301353

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4819243

http://www.w3.org/2001/XMLSchema#string